-
1
-
-
0032053823
-
The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
-
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
-
(1998)
Cancer Res
, vol.58
, pp. 1408-1416
-
-
Brown, J.M.1
Giaccia, A.J.2
-
2
-
-
0142166332
-
Targeting HIF-1 for cancer therapy
-
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 721-732
-
-
Semenza, G.L.1
-
3
-
-
0036359548
-
Hypoxia - a key regulatory factor in tumour growth
-
Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 38-47
-
-
Harris, A.L.1
-
5
-
-
0037008770
-
Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway
-
Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002;31:27975-81.
-
(2002)
J Biol Chem
, vol.31
, pp. 27975-27981
-
-
Treins, C.1
Giorgetti-Peraldi, S.2
Murdaca, J.3
Semenza, G.L.4
Van Obberghen, E.5
-
6
-
-
0036569704
-
Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells
-
Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82.
-
(2002)
Cancer Res
, vol.62
, pp. 2478-2482
-
-
Mabjeesh, N.J.1
Post, D.E.2
Willard, M.T.3
-
7
-
-
0037119415
-
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
-
Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 2002;277:29936-44.
-
(2002)
J Biol Chem
, vol.277
, pp. 29936-29944
-
-
Isaacs, J.S.1
Jung, Y.J.2
Mimnaugh, E.G.3
Martinez, A.4
Cuttitta, F.5
Neckers, L.M.6
-
8
-
-
10744231706
-
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
-
Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;4:363-75.
-
(2003)
Cancer Cell
, vol.4
, pp. 363-375
-
-
Mabjeesh, N.J.1
Escuin, D.2
LaVallee, T.M.3
-
9
-
-
0035871942
-
Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells
-
Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001;61:947-54.
-
(2001)
Biochem Pharmacol
, vol.61
, pp. 947-954
-
-
Chun, Y.S.1
Yeo, E.J.2
Choi, E.3
-
10
-
-
0036682284
-
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway
-
Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62:4316-24.
-
(2002)
Cancer Res
, vol.62
, pp. 4316-4324
-
-
Rapisarda, A.1
Uranchimeg, B.2
Scudiero, D.A.3
-
11
-
-
25444523184
-
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity
-
Kong D, Park EJ, Stephen AG, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005;65:9047-55.
-
(2005)
Cancer Res
, vol.65
, pp. 9047-9055
-
-
Kong, D.1
Park, E.J.2
Stephen, A.G.3
-
12
-
-
0033616948
-
Aromatic hydrocarbon nuclear translocator as a common component for the hypoxia- and dioxin-induced gene expression
-
Park H. Aromatic hydrocarbon nuclear translocator as a common component for the hypoxia- and dioxin-induced gene expression. Mol Cells 1999;9:172-8.
-
(1999)
Mol Cells
, vol.9
, pp. 172-178
-
-
Park, H.1
-
13
-
-
1242271198
-
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications
-
Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64:1475-82.
-
(2004)
Cancer Res
, vol.64
, pp. 1475-1482
-
-
Rapisarda, A.1
Uranchimeg, B.2
Sordet, O.3
Pommier, Y.4
Shoemaker, R.H.5
Melillo, G.6
-
14
-
-
0026580275
-
Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo [1,4] dioxin-1-carboxamides: A new class of weakly binding DNA-intercalating agents
-
Lee HH, Palmer BD, Boyd M, Baguley BC, Denny WA. Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo [1,4] dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents. J Med Chem 1992;35:258-66.
-
(1992)
J Med Chem
, vol.35
, pp. 258-266
-
-
Lee, H.H.1
Palmer, B.D.2
Boyd, M.3
Baguley, B.C.4
Denny, W.A.5
-
15
-
-
3843052715
-
HIF-1: A target for cancer, ischemia, and inflammation - too good to be true?
-
Melillo G. HIF-1: a target for cancer, ischemia, and inflammation - too good to be true? Cell Cycle 2004;3:154-5.
-
(2004)
Cell Cycle
, vol.3
, pp. 154-155
-
-
Melillo, G.1
-
17
-
-
33746564193
-
The hypoxic inducible stress response as a target for cancer drug discovery
-
Welsh SJ, Koh MY, Powls G, The hypoxic inducible stress response as a target for cancer drug discovery. Semin Oncol 2006;4:486-97.
-
(2006)
Semin Oncol
, vol.4
, pp. 486-497
-
-
Welsh, S.J.1
Koh, M.Y.2
Powls, G.3
-
18
-
-
33749362031
-
Inhibiting hypoxia-inducible factor 1 for cancer therapy
-
Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006;4:601-5.
-
(2006)
Mol Cancer Res
, vol.4
, pp. 601-605
-
-
Melillo, G.1
-
19
-
-
13544254815
-
Topoisomerase II: Untangling its contribution at the centromere
-
Porter AC, Farr CJ. Topoisomerase II: untangling its contribution at the centromere. Chromosome Res 2004;12:569-83.
-
(2004)
Chromosome Res
, vol.12
, pp. 569-583
-
-
Porter, A.C.1
Farr, C.J.2
-
20
-
-
1842480104
-
Functional compatibility between isoform α and β of type II DNA topoisomerase
-
Sakaguchi A, Kikuchi A. Functional compatibility between isoform α and β of type II DNA topoisomerase. J Cell Sci 2004;117:1047-54.
-
(2004)
J Cell Sci
, vol.117
, pp. 1047-1054
-
-
Sakaguchi, A.1
Kikuchi, A.2
-
21
-
-
12444269092
-
Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIα
-
Akimitsu N, Adachi N, Hirai H, et al. Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIα. Genes Cells 2003;8:393-402.
-
(2003)
Genes Cells
, vol.8
, pp. 393-402
-
-
Akimitsu, N.1
Adachi, N.2
Hirai, H.3
-
22
-
-
0032509551
-
Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells
-
Grue P, Grasser A, Sehested M, et al. Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells. J Biol Chem 1998;273:33660-6.
-
(1998)
J Biol Chem
, vol.273
, pp. 33660-33666
-
-
Grue, P.1
Grasser, A.2
Sehested, M.3
-
23
-
-
0031722207
-
Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents
-
Perrin D, van Hille B, Hill BT. Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents. Biochem Pharmacol 1998;56:503-7.
-
(1998)
Biochem Pharmacol
, vol.56
, pp. 503-507
-
-
Perrin, D.1
van Hille, B.2
Hill, B.T.3
-
24
-
-
0034193276
-
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs
-
Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000;60:2429-34.
-
(2000)
Cancer Res
, vol.60
, pp. 2429-2434
-
-
Ogiso, Y.1
Tomida, A.2
Lei, S.3
Omura, S.4
Tsuruo, T.5
-
25
-
-
2942733275
-
DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1α in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX
-
Kaluzova M, Kaluz S, Lerman MI, Stanbridge EJ. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1α in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol 2004;24:5757-66.
-
(2004)
Mol Cell Biol
, vol.24
, pp. 5757-5766
-
-
Kaluzova, M.1
Kaluz, S.2
Lerman, M.I.3
Stanbridge, E.J.4
-
26
-
-
0023887575
-
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides
-
Palmer BD, Rewcastle GW, Atwell GJ, Baguley BC, Denny WA. Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides. J Med Chem 1998;31:707-12.
-
(1998)
J Med Chem
, vol.31
, pp. 707-712
-
-
Palmer, B.D.1
Rewcastle, G.W.2
Atwell, G.J.3
Baguley, B.C.4
Denny, W.A.5
-
27
-
-
0035300559
-
Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine- 4-carboxamide and DNA-intercalating analogues
-
Osman S, Rowlinson-Busza G, Luthra SK, et al. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine- 4-carboxamide and DNA-intercalating analogues Cancer Res 2001;61:2935-44.
-
(2001)
Cancer Res
, vol.61
, pp. 2935-2944
-
-
Osman, S.1
Rowlinson-Busza, G.2
Luthra, S.K.3
|